Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cibus, Inc.CBUS · Entity 6658 | Director | June 02, 2026 | June 04, 2026 |
| KYNTRA BIO, INC.FGEN · Entity 7431 | Director | May 26, 2021 | May 28, 2021 |
| Royalty Pharma plcRPRX · Entity 3100 | Director | February 20, 2024 | February 23, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cibus, Inc.
Report date June 02, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right-to-Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2036-06-02 | Direct | 77,586 |
Reported balance
After 2026-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-02 · Grant · Acquired 77,586 · Balance 77,586 F1: The Options vest in full, subject to the Director's continued service, the earlier of (1) the first anniversary of the grant date and (2) the date of the Company's next annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The Options vest in full, subject to the Director's continued service, the earlier of (1) the first anniversary of the grant date and (2) the date of the Company's next annual meeting of shareholders.
KYNTRA BIO, INC.
Report date May 26, 2021 · Filed May 28, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 395,750 |
Reported balance
After 2021-05-26 transaction · row 1
1 source rowRow 1 · 2021-05-26 · Grant · Acquired 4,700 · Balance 395,750 F1: Represents the grant of restricted stock units that vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.86 · Expires 2031-05-25 | Direct | 7,800 |
Reported balance
After 2021-05-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-05-26 · Grant · Acquired 7,800 · Balance 7,800 F3: Options vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 605,713 |
Reported balance
Holding disclosure · report date 2021-05-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 605,713 F2: Shares are held by New Ventures I, LLC. The reporting person is Managing Member of New Ventures I, LLC and has voting and investment control with respect to the shares held by New Ventures I, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units that vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.
F2: Shares are held by New Ventures I, LLC. The reporting person is Managing Member of New Ventures I, LLC and has voting and investment control with respect to the shares held by New Ventures I, LLC.
F3: Options vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.
Royalty Pharma plc
Report date February 20, 2024 · Filed February 23, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary SharesSEC Table I · non-derivative | Direct | 320,099 |
Reported balance
After 2024-02-20 transaction · row 1
1 source rowRow 1 · 2024-02-20 · Conversion · Acquired 300,000 · Balance 320,099 F1: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. |
| LP interests in RPI US Partners 2019, LPSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 270,000 |
Reported balance
After 2024-02-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-20 · Conversion · Disposed 30,000 · Balance 270,000 F1: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F2: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. |
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy New Ventures III LLC | 85,187 |
Reported balance
Holding disclosure · report date 2024-02-20 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 85,187 |
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy Spouse | 15,000 |
Reported balance
Holding disclosure · report date 2024-02-20 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 15,000 |
Filing footnotes · ownership attribution and instrument terms
F1: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.
F2: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Intra-Cellular Therapies, Inc.
Report date April 02, 2025 · Filed April 02, 2025
Section 16 reporting ended · disclosed 2025-04-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 1
1 source rowRow 1 · 2025-04-02 · Disposition to issuer · Disposed 131,512 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and conditions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Company Shares") issued and outstanding immediately prior to the Effective Time (other than certain Company Shares canceled pursuant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.58 · Expires 2025-06-15 | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-04-02 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.35 · Expires 2026-06-13 | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-04-02 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.45 · Expires 2027-06-26 | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-04-02 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.45 · Expires 2031-06-20 | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-04-02 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.48 · Expires 2032-06-08 | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-04-02 · Disposition to issuer · Disposed 16,757 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.79 · Expires 2033-06-22 | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-04-02 · Disposition to issuer · Disposed 7,009 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.77 · Expires 2034-06-13 | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-04-02 · Disposition to issuer · Disposed 4,322 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-04-02 · Disposition to issuer · Disposed 2,951 · Balance 0 F5: Each restricted stock unit (each, a "Company RSU") represented a contingent right to receive one Company Share. F6: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances. F7: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and conditions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time").
F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Company Shares") issued and outstanding immediately prior to the Effective Time (other than certain Company Shares canceled pursuant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings.
F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.
F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.
F5: Each restricted stock unit (each, a "Company RSU") represented a contingent right to receive one Company Share.
F6: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances.
F7: Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 21, 2021 Filed Jun 22, 2021 20:21 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $43.45 | $0.00 |
DisclosureSEC source: 0001209191-21-042389 · doc4.xml · derivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-20 Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 00:13 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 273,650 | $45.26 | $12,385,399.00 |
DisclosureSEC source: 0000950103-21-008572 · dp152446_4-riggs.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By New Ventures III LLC Disclosed balance after: 2,081,540 Read SEC document |
| May 27, 2021 Filed Jun 4, 2021 20:05 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Exercise / conversionRestricted Stock Units · Derivative | 13,767 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038187 · doc4.xml · derivative · entry 3 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,767 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: On May 27, 2020, the reporting person was granted 13,767 restricted stock units, vesting on the first anniversary of the grant date (May 27, 2021). F3 · derivative.expiration_date: On May 27, 2020, the reporting person was granted 13,767 restricted stock units, vesting on the first anniversary of the grant date (May 27, 2021). Read SEC document |
| May 27, 2021 Filed Jun 4, 2021 20:05 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Exercise / conversionCommon Stock | 13,767 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-038187 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| May 26, 2021 Filed May 28, 2021 23:08 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 7,800 | $0.00 Strike: $20.86 | $0.00 |
DisclosureSEC source: 0001209191-21-036683 · doc4.xml · derivative · entry 3 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2031-05-25 F3 · derivative.exercise_date: Options vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document |
| May 26, 2021 Filed May 28, 2021 23:08 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 4,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-036683 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395,750 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document |
| May 07, 2021 Filed May 12, 2021 01:00 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionLP interests in RPI US Partners 2019, LP · Derivative | 235,519 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-007074 · dp150860_4-riggs.xml · derivative · entry 7 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By New Ventures III LLC Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 2,355,190 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F2 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. F2 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. Read SEC document |
| May 07, 2021 Filed May 12, 2021 01:00 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionLP interests in RPI US Partners 2019, LP · Derivative | 67,976 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-007074 · dp150860_4-riggs.xml · derivative · entry 6 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 541,751 Underlying: Class A Ordinary Shares · 679,760 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F2 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. F2 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. Read SEC document |
| May 07, 2021 Filed May 12, 2021 01:00 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionClass A Ordinary Shares | 2,355,190 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-007074 · dp150860_4-riggs.xml · nonDerivative · entry 2 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By New Ventures III LLC Disclosed balance after: 2,355,190 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F1 · price: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. Read SEC document |
| May 07, 2021 Filed May 12, 2021 01:00 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionClass A Ordinary Shares | 679,760 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-007074 · dp150860_4-riggs.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 679,760 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F1 · price: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 21:29 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantCommon Stock | 464 | $33.93 | $15,743.52 |
DisclosureSEC source: 0001209191-21-024728 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,941 Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 23:03 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantCommon Stock | 495 | $31.80 | $15,741.00 |
DisclosureSEC source: 0001209191-21-001490 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,477 Read SEC document |
| October 20, 2020 Filed Oct 23, 2020 01:48 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionLP interests in RPI US Partners 2019, LP · Derivative | 46,320 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950103-20-020496 · dp139167_4-riggs.xml · derivative · entry 4 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,681 Underlying: Class A Ordinary Shares · 463,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, ("Holdings"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. No additional value was paid by the Reporting Person in connection with the exchange. F1 · kind: These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, ("Holdings"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. No additional value was paid by the Reporting Person in connection with the exchange. F2 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F2 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F3 · balance_after: Includes RPI US LP Interests convertible into 172,210 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share. Read SEC document |
| October 20, 2020 Filed Oct 23, 2020 01:48 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 463,200 | $42.00 | $19,454,400.00 |
DisclosureSEC source: 0000950103-20-020496 · dp139167_4-riggs.xml · nonDerivative · entry 2 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| October 20, 2020 Filed Oct 23, 2020 01:48 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionClass A Ordinary Shares | 463,200 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-20-020496 · dp139167_4-riggs.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 463,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, ("Holdings"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. No additional value was paid by the Reporting Person in connection with the exchange. F1 · price: These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, ("Holdings"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. No additional value was paid by the Reporting Person in connection with the exchange. Read SEC document |
| October 20, 2020 Filed Oct 23, 2020 23:11 UTC Amendment | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 463,200 | $42.00 | $19,454,400.00 |
DisclosureSEC source: 0000950103-20-020542 · dp139211_4a-riggs.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On October 22, 2020, the Reporting Person filed a Form 4 reporting this sale. This amendment is being filed to report that this sale was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 15,000 Class A Ordinary Shares, with the purchase of Class A Ordinary Shares by the Spouse of the Reporting Person on June 18, 2020. The Reporting Person has voluntarily disgorged to the Issuer the full amount of the resulting statutory "profit" calculated pursuant to Section 16(b) of the Securities Exchange Act of 1934, as amended. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 20:22 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantCommon Stock | 613 | $25.66 | $15,729.58 |
DisclosureSEC source: 0001209191-20-053127 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,982 Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 23:02 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantCommon Stock | 613 | $25.67 | $15,735.71 |
DisclosureSEC source: 0001209191-20-040681 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,369 Read SEC document |
| June 25, 2020 Filed Jun 27, 2020 01:07 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Exercise / conversionRestricted Stock Units · Derivative | 14,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-039189 · doc4.xml · derivative · entry 3 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,005 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: On June 25, 2019, the reporting person was granted 14,005 restricted stock units, vesting on the first anniversary of the grant date (June 25, 2020). F3 · derivative.expiration_date: On June 25, 2019, the reporting person was granted 14,005 restricted stock units, vesting on the first anniversary of the grant date (June 25, 2020). Read SEC document |
| June 25, 2020 Filed Jun 27, 2020 01:07 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Exercise / conversionCommon Stock | 14,005 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-039189 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| June 18, 2020 Filed Jun 24, 2020 01:14 UTC | Royalty Pharma plc RPRX · Entity 3100 | PurchaseClass A Ordinary Shares | 15,000 | $28.00 | $420,000.00 |
DisclosureSEC source: 0000950103-20-012253 · dp130801_4-riggs.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 15,000 Read SEC document |
| June 18, 2020 Filed Feb 27, 2021 00:41 UTC Amendment | Royalty Pharma plc RPRX · Entity 3100 | ConversionLP interests in RPI International Holdings 2019, LP · Derivative | 111,301 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-003200 · dp146949_4a-riggs.xml · derivative · entry 4 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By New Ventures Select LLC Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 1,113,010 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP ("RPI Intl. LP"). Each limited partnership interest in RPI Intl. LP ("RPI Intl. LP Interest") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, ("Holdings") or directly for ten Class A Ordinary Shares. Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value was paid by the Reporting Person in connection with the exchange. F1 · kind: These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP ("RPI Intl. LP"). Each limited partnership interest in RPI Intl. LP ("RPI Intl. LP Interest") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, ("Holdings") or directly for ten Class A Ordinary Shares. Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value was paid by the Reporting Person in connection with the exchange. F2 · kind: This exchange was effected by the General Partner of RPI Intl. LP in accordance with a provision of the Limited Partnership Agreement of RPI Intl. LP applicable in the event of the public offering of the Issuer's Class A Ordinary Shares. The exchange applied to all holders of RPI Intl. LP Interests that did not opt out of participation. F3 · derivative.exercise_date: Represents limited partnership interests in RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F3 · derivative.expiration_date: Represents limited partnership interests in RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F5 · balance_after: Following this transaction, included 8,681 RPI Intl. LP Interests convertible into 86,810 Class A Ordinary Shares that were subject to forfeiture if and when the Class A Ordinary Shares attained a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. All such interests were forfeited on December 16, 2020. Read SEC document |
| June 18, 2020 Filed Feb 27, 2021 00:41 UTC Amendment | Royalty Pharma plc RPRX · Entity 3100 | ConversionLP interests in RPI International Holdings 2019, LP · Derivative | 458,707 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-003200 · dp146949_4a-riggs.xml · derivative · entry 3 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By New Ventures I LLC Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 4,587,070 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP ("RPI Intl. LP"). Each limited partnership interest in RPI Intl. LP ("RPI Intl. LP Interest") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, ("Holdings") or directly for ten Class A Ordinary Shares. Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value was paid by the Reporting Person in connection with the exchange. F1 · kind: These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP ("RPI Intl. LP"). Each limited partnership interest in RPI Intl. LP ("RPI Intl. LP Interest") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, ("Holdings") or directly for ten Class A Ordinary Shares. Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value was paid by the Reporting Person in connection with the exchange. F2 · kind: This exchange was effected by the General Partner of RPI Intl. LP in accordance with a provision of the Limited Partnership Agreement of RPI Intl. LP applicable in the event of the public offering of the Issuer's Class A Ordinary Shares. The exchange applied to all holders of RPI Intl. LP Interests that did not opt out of participation. F3 · derivative.exercise_date: Represents limited partnership interests in RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F3 · derivative.expiration_date: Represents limited partnership interests in RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F4 · balance_after: Following this transaction, included 35,778 RPI Intl. LP Interests convertible into 357,780 Class A Ordinary Shares that were subject to forfeiture if and when the Class A Ordinary Shares attained a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. All such interests were forfeited on December 16, 2020. Read SEC document |
| June 18, 2020 Filed Feb 27, 2021 00:41 UTC Amendment | Royalty Pharma plc RPRX · Entity 3100 | ConversionClass A Ordinary Shares | 1,113,010 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-003200 · dp146949_4a-riggs.xml · nonDerivative · entry 2 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By New Ventures Select LLC Disclosed balance after: 1,113,010 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP ("RPI Intl. LP"). Each limited partnership interest in RPI Intl. LP ("RPI Intl. LP Interest") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, ("Holdings") or directly for ten Class A Ordinary Shares. Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value was paid by the Reporting Person in connection with the exchange. F2 · kind: This exchange was effected by the General Partner of RPI Intl. LP in accordance with a provision of the Limited Partnership Agreement of RPI Intl. LP applicable in the event of the public offering of the Issuer's Class A Ordinary Shares. The exchange applied to all holders of RPI Intl. LP Interests that did not opt out of participation. F1 · price: These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP ("RPI Intl. LP"). Each limited partnership interest in RPI Intl. LP ("RPI Intl. LP Interest") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, ("Holdings") or directly for ten Class A Ordinary Shares. Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value was paid by the Reporting Person in connection with the exchange. Read SEC document |
| June 18, 2020 Filed Feb 27, 2021 00:41 UTC Amendment | Royalty Pharma plc RPRX · Entity 3100 | ConversionClass A Ordinary Shares | 4,587,070 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-003200 · dp146949_4a-riggs.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By New Ventures I LLC Disclosed balance after: 4,587,070 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP ("RPI Intl. LP"). Each limited partnership interest in RPI Intl. LP ("RPI Intl. LP Interest") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, ("Holdings") or directly for ten Class A Ordinary Shares. Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value was paid by the Reporting Person in connection with the exchange. F2 · kind: This exchange was effected by the General Partner of RPI Intl. LP in accordance with a provision of the Limited Partnership Agreement of RPI Intl. LP applicable in the event of the public offering of the Issuer's Class A Ordinary Shares. The exchange applied to all holders of RPI Intl. LP Interests that did not opt out of participation. F1 · price: These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP ("RPI Intl. LP"). Each limited partnership interest in RPI Intl. LP ("RPI Intl. LP Interest") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, ("Holdings") or directly for ten Class A Ordinary Shares. Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value was paid by the Reporting Person in connection with the exchange. Read SEC document |
| June 15, 2020 Filed Jun 24, 2020 01:14 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantLP interests in RPI International Holdings 2019, LP · Derivative | 119,982 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950103-20-012253 · dp130801_4-riggs.xml · derivative · entry 6 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By New Ventures Select LLC Disclosed balance after: 119,982 Underlying: Class A Ordinary Shares · 1,199,820 shares Expires not disclosed F1 · kind: The Reporting Person acquired beneficial ownership of Class B Interests in Royalty Pharma Holdings, Ltd. ("Holdings") and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP ("RPI US LP") and RPI International Holdings 2019, LP ("RPI Intl. LP") for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020. F5 · derivative.exercise_date: Represents limited partnership interests in RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F5 · derivative.expiration_date: Represents limited partnership interests in RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F7 · balance_after: Includes RPI Intl. LP Interests convertible into 86,810 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share. Read SEC document |
| June 15, 2020 Filed Jun 24, 2020 01:14 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantLP interests in RPI International Holdings 2019, LP · Derivative | 494,485 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950103-20-012253 · dp130801_4-riggs.xml · derivative · entry 5 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By New Ventures I LLC Disclosed balance after: 494,485 Underlying: Class A Ordinary Shares · 4,944,850 shares Expires not disclosed F1 · kind: The Reporting Person acquired beneficial ownership of Class B Interests in Royalty Pharma Holdings, Ltd. ("Holdings") and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP ("RPI US LP") and RPI International Holdings 2019, LP ("RPI Intl. LP") for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020. F5 · derivative.exercise_date: Represents limited partnership interests in RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F5 · derivative.expiration_date: Represents limited partnership interests in RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F6 · balance_after: Includes RPI Intl. LP Interests convertible into 357,780 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share. Read SEC document |
| June 15, 2020 Filed Jun 24, 2020 01:14 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantLP interests in RPI US Partners 2019, LP · Derivative | 253,889 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950103-20-012253 · dp130801_4-riggs.xml · derivative · entry 4 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By New Ventures III LLC Disclosed balance after: 253,889 Underlying: Class A Ordinary Shares · 2,538,890 shares Expires not disclosed F1 · kind: The Reporting Person acquired beneficial ownership of Class B Interests in Royalty Pharma Holdings, Ltd. ("Holdings") and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP ("RPI US LP") and RPI International Holdings 2019, LP ("RPI Intl. LP") for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020. F2 · derivative.exercise_date: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F2 · derivative.expiration_date: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F4 · balance_after: Includes RPI US LP Interests convertible into 183,700 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share. Read SEC document |
| June 15, 2020 Filed Jun 24, 2020 01:14 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantLP interests in RPI US Partners 2019, LP · Derivative | 435,267 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950103-20-012253 · dp130801_4-riggs.xml · derivative · entry 3 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 435,267 Underlying: Class A Ordinary Shares · 4,352,670 shares Expires not disclosed F1 · kind: The Reporting Person acquired beneficial ownership of Class B Interests in Royalty Pharma Holdings, Ltd. ("Holdings") and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP ("RPI US LP") and RPI International Holdings 2019, LP ("RPI Intl. LP") for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020. F2 · derivative.exercise_date: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F2 · derivative.expiration_date: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. Read SEC document |
| June 15, 2020 Filed Jun 24, 2020 01:14 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantLP interests in RPI US Partners 2019, LP · Derivative | 238,001 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950103-20-012253 · dp130801_4-riggs.xml · derivative · entry 2 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,001 Underlying: Class A Ordinary Shares · 2,380,010 shares Expires not disclosed F1 · kind: The Reporting Person acquired beneficial ownership of Class B Interests in Royalty Pharma Holdings, Ltd. ("Holdings") and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP ("RPI US LP") and RPI International Holdings 2019, LP ("RPI Intl. LP") for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020. F2 · derivative.exercise_date: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F2 · derivative.expiration_date: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F3 · balance_after: Includes RPI US LP Interests convertible into 172,210 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share. Read SEC document |
| June 04, 2020 Filed Jun 9, 2020 00:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 7,800 | $0.00 Strike: $32.69 | $0.00 |
DisclosureSEC source: 0001209191-20-035155 · doc4.xml · derivative · entry 3 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2030-06-03 F3 · derivative.exercise_date: Options vest on the earlier of June 4, 2021 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document |
| June 04, 2020 Filed Jun 9, 2020 00:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 4,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035155 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 391,050 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 4, 2021 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document |
| May 27, 2020 Filed May 28, 2020 23:03 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantRestricted Stock Units · Derivative | 13,767 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-032734 · doc4.xml · derivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,767 Underlying: Common Stock · 13,767 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: On May 27, 2020, the reporting person was granted 13,767 restricted stock units, vesting on the first anniversary of the grant date (May 27, 2021). F2 · derivative.expiration_date: On May 27, 2020, the reporting person was granted 13,767 restricted stock units, vesting on the first anniversary of the grant date (May 27, 2021). Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 21:50 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantCommon Stock | 1,024 | $15.37 | $15,738.88 |
DisclosureSEC source: 0001209191-20-022748 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,751 Read SEC document |
| December 31, 2019 Filed Jan 4, 2020 02:12 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantCommon Stock | 422 | $34.31 | $14,478.82 |
DisclosureSEC source: 0001209191-20-001463 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,727 Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 21:37 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantCommon Stock | 1,941 | $7.47 | $14,499.27 |
DisclosureSEC source: 0001209191-19-051861 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,305 Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 21:03 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantCommon Stock | 1,117 | $12.98 | $14,498.66 |
DisclosureSEC source: 0001209191-19-040399 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,364 Read SEC document |
| June 25, 2019 Filed Jun 26, 2019 20:33 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantRestricted Stock Units · Derivative | 14,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-039107 · doc4.xml · derivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,005 Underlying: Common Stock · 14,005 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: On June 25, 2019, the reporting person was granted 14,005 restricted stock units, vesting on the first anniversary of the grant date (June 25, 2020). F2 · derivative.expiration_date: On June 25, 2019, the reporting person was granted 14,005 restricted stock units, vesting on the first anniversary of the grant date (June 25, 2020). Read SEC document |
| June 18, 2019 Filed Oct 15, 2024 22:00 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Exercise / conversionRestricted Stock Units · Derivative | 14,189 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-114785 · ownership.xml · derivative · entry 2 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,189 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: On June 18, 2018, the reporting person was granted 14,189 restricted stock units, vesting on the first anniversary of the grant date (June 18, 2019). F2 · derivative.expiration_date: On June 18, 2018, the reporting person was granted 14,189 restricted stock units, vesting on the first anniversary of the grant date (June 18, 2019). Read SEC document |
| June 18, 2019 Filed Oct 15, 2024 22:00 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Exercise / conversionCommon Stock | 14,189 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-114785 · ownership.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 23:19 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 7,800 | $0.00 Strike: $39.03 | $0.00 |
DisclosureSEC source: 0001209191-19-035664 · doc4.xml · derivative · entry 3 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2029-06-05 F3 · derivative.exercise_date: Options vest on the earlier of June 5, 2020 or the date of the next annual meeting of stockholders. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 23:19 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 4,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-035664 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,350 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 5, 2020 or the date of the next annual meeting of stockholders. Read SEC document |
| March 31, 2019 Filed Apr 2, 2019 22:56 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantCommon Stock | 1,190 | $12.18 | $14,494.20 |
DisclosureSEC source: 0001209191-19-022715 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,247 Read SEC document |
| December 31, 2018 Filed Jan 4, 2019 01:15 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantCommon Stock | 1,273 | $11.39 | $14,499.47 |
DisclosureSEC source: 0001209191-19-001545 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,057 Read SEC document |
| September 30, 2018 Filed Oct 3, 2018 00:08 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantCommon Stock | 668 | $21.70 | $14,495.60 |
DisclosureSEC source: 0001209191-18-053528 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,784 Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 23:11 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GiftCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052626 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,650 Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:20 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantCommon Stock | 820 | $17.67 | $14,489.40 |
DisclosureSEC source: 0001209191-18-041038 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,116 Read SEC document |
| June 18, 2018 Filed Jun 20, 2018 20:52 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantRestricted Stock Units · Derivative | 14,189 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038799 · doc4.xml · derivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,189 Underlying: Common Stock · 14,189 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: On June 18, 2018, the reporting person was granted 14,189 restricted stock units, vesting on the first anniversary of the grant date (June 18, 2019). F2 · derivative.expiration_date: On June 18, 2018, the reporting person was granted 14,189 restricted stock units, vesting on the first anniversary of the grant date (June 18, 2019). Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 23:39 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $55.30 | $0.00 |
DisclosureSEC source: 0001209191-18-036515 · doc4.xml · derivative · entry 3 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-06-05 F3 · derivative.exercise_date: Options vest on the earlier of June 6, 2019 or the date of the next annual meeting of stockholders. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 23:39 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 3,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-036515 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382,900 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 6, 2019 or the date of the next annual meeting of stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.